ATE64141T1 - Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen. - Google Patents

Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen.

Info

Publication number
ATE64141T1
ATE64141T1 AT84113943T AT84113943T ATE64141T1 AT E64141 T1 ATE64141 T1 AT E64141T1 AT 84113943 T AT84113943 T AT 84113943T AT 84113943 T AT84113943 T AT 84113943T AT E64141 T1 ATE64141 T1 AT E64141T1
Authority
AT
Austria
Prior art keywords
digitalis
antibodies
immunologically
intoxications
therapy
Prior art date
Application number
AT84113943T
Other languages
German (de)
English (en)
Inventor
Hans-Georg Dr Rer Nat Batz
Herbert Dr Med Jungfer
Helmut Dr Rer Nat Lenz
Albert Dr Rer Nat Roeder
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Application granted granted Critical
Publication of ATE64141T1 publication Critical patent/ATE64141T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT84113943T 1983-11-26 1984-11-17 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen. ATE64141T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19833342870 DE3342870A1 (de) 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
EP84113943A EP0143413B1 (de) 1983-11-26 1984-11-17 Digitalis-Antikörper, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von Digitalis-Intoxikationen

Publications (1)

Publication Number Publication Date
ATE64141T1 true ATE64141T1 (de) 1991-06-15

Family

ID=6215371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84113943T ATE64141T1 (de) 1983-11-26 1984-11-17 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen.

Country Status (8)

Country Link
US (1) US4742159A (enExample)
EP (1) EP0143413B1 (enExample)
JP (1) JPS60132922A (enExample)
AT (1) ATE64141T1 (enExample)
CA (1) CA1242393A (enExample)
DE (2) DE3342870A1 (enExample)
ES (1) ES8600770A1 (enExample)
SU (1) SU1455999A3 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
JPH0623761B2 (ja) * 1988-12-09 1994-03-30 株式会社ピーシーシーテクノロジー 配糖化した化合物を生産する細胞の検出方法
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
ATE183513T1 (de) * 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US7348294B2 (en) * 2000-05-25 2008-03-25 Kaneka Corporation Adsorbent and method for adsorbing cardiac glycoside
FR2810667B1 (fr) * 2000-06-23 2004-09-03 Warner Lambert Co Procede d'isolement et de purification d'une proteine, et proteine obtenue
US6987079B2 (en) 2001-08-14 2006-01-17 W.R. Grace & Co.-Conn. Supported catalyst systems
US6802966B2 (en) 2001-08-14 2004-10-12 W. R. Grace & Co. Conn. Solid compositions for selective adsorption from complex mixtures
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
CN101505795B (zh) 2006-07-03 2013-02-13 查尔斯·戴维·阿代尔 用于调节细胞粘附分子表达的组合物
EP2370092A1 (en) 2008-12-03 2011-10-05 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
WO2013022599A1 (en) 2011-08-05 2013-02-14 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
EP2912064B1 (en) 2012-10-24 2019-04-24 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
ES2973870T3 (es) 2016-03-29 2024-06-24 Univ Texas Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
WO2018222689A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN121609797A (zh) 2017-06-06 2026-03-06 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
JP2020536855A (ja) 2017-09-26 2020-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法
WO2019236590A1 (en) 2018-06-04 2019-12-12 University Of Maryland, Baltimore Methods for preventing acute kidney injury
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
CN113736744B (zh) * 2021-10-14 2023-07-18 江南大学 洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790475A (en) * 1972-03-27 1974-02-05 Corning Glass Works Porous glass support material
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US4081246A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Solid phase column immunoassay procedure employing novel immunochemical composites
US4081245A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Immunoassay procedure employing novel immunochemical composites
US4232004A (en) * 1977-09-21 1980-11-04 American National Red Cross Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
US4434234A (en) * 1981-04-02 1984-02-28 The Upjohn Company Method and kit for silver staining substances supported in matrix

Also Published As

Publication number Publication date
JPH0324480B2 (enExample) 1991-04-03
ES537909A0 (es) 1985-11-01
ES8600770A1 (es) 1985-11-01
CA1242393A (en) 1988-09-27
EP0143413A2 (de) 1985-06-05
DE3342870A1 (de) 1985-06-05
EP0143413B1 (de) 1991-06-05
DE3484673D1 (de) 1991-07-11
SU1455999A3 (ru) 1989-01-30
JPS60132922A (ja) 1985-07-16
US4742159A (en) 1988-05-03
EP0143413A3 (en) 1988-07-20

Similar Documents

Publication Publication Date Title
ATE64141T1 (de) Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen.
Edelman et al. Immunological studies of human γ-globulin: Relation of the precipitin lines of whole γ-globulin to those of the fragments produced by papain
Nishi et al. Purification of human, dog and rabbit α-fetoprotein by immunoadsorbents of Sepharose coupled with anti-human α-fetoprotein
Feltkamp Conjugation of Fluorescein Isothiocyanate to Antibodies I. EXPERIMENT ON THE CONDITIONS OF CONJUGATION.
ATE123780T1 (de) Verfahren zur verwendung und herstellung von peptiden.
Fullmer et al. Bovine intestinal calcium-binding proteins: Purification and some properties
WO2003059935A3 (en) Methods for purifying protein
SE7909488L (sv) Hemjernrikat aminosyrapreparat och forfarande for framstellning av hemjernrikade aminosyrapreparat fran hemproteiner
DE69028513D1 (de) Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
Ibsen et al. Enzyme‐linked immunosorbent assay of the D2‐glycoprotein
DE3486350D1 (de) VERFAHREN ZUR ISOLIERUNG EINES PROTEINS AUS EINER DIESES PROTEIN ENTHALTENDEN MISCHUNG UNTER VERWENDUNG EINES KONFORMATIONSSPEZIFISCHEN ANTIKöRPERS.
DE3887750D1 (de) Selektive entfernung von immunkomplexen.
HU9602570D0 (en) Process for producing immunoglobulines from fractions produced with fractioning human blood-plasma
KR900003207A (ko) 트롬빈 결합성 물질 및 이의 제조방법
Karamova et al. Conformational variants of human alpha-fetoprotein
RU2094078C1 (ru) Хроматографический способ выделения альфа-фетопротеина
Davis et al. Diazotized m-aminobenzyloxymethylcellulose as the insoluble matrix for an immunoadsorbent used in the purification of antigens and antibodies
Bock et al. Characterization of the D2-cell adhesion molecule
Hoag et al. Optimal conditions for isolating human placental alkaline phosphatase by immunosorption
Goudswaard et al. Isolation of equine IgG (T) by hydrophobic interaction chromatography
ATE9906T1 (de) Verfahren zum herstellen und erhalten von anaphylatoxin und cocytotaxin enthaltenden leukotaxin-praeparaten und von anaphylatoxinund cocytotaxin-proteinen in einer molekular homogenen und biologisch aktiven form.
Donini et al. Immunohistochemical typing of amyloid on hydroxyethyl-methacrylate-embedded renal biopsies
Matsuoka et al. Isolation and characterization of IgA produced by an established human lymphocytoid cell line
ES2080804T3 (es) Separacion de anticuerpos anti-metal quelato.
Stone et al. Chromatographic separation of gram quantities of immunoglobulins from porcine colostrum against transmissible gastroenteritis virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time